Europe Peripheral Artery Disease Market Size, Share & Trends Analysis Report By Product Type (Drugs, and Devices), By End User (Hospitals, and Specialty Clinics), By Country and Growth Forecast, 2024 - 2031

Europe Peripheral Artery Disease Market Size, Share & Trends Analysis Report By Product Type (Drugs, and Devices), By End User (Hospitals, and Specialty Clinics), By Country and Growth Forecast, 2024 - 2031

The Europe Peripheral Artery Disease Market would witness market growth of 6.5% CAGR during the forecast period (2024-2031).

The Germany market dominated the Europe Peripheral Artery Disease Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $480.3 million by 2031. The UK market is exhibiting a CAGR of 5.7% during (2024 - 2031). Additionally, The France market would experience a CAGR of 7.4% during (2024 - 2031).

The diagnosis and treatment of peripheral arterial disease have been significantly improved as a result of technological breakthroughs in medical equipment and minimally invasive treatments, which has further contributed to the expansion of the market. Innovations like drug-eluting stents, atherectomy devices, and advanced imaging technologies like intravascular ultrasound (IVUS) and optical coherence tomography (OCT) have revolutionized PAD management. These technologies enable precise diagnosis, targeted treatment, and improved patient outcomes.

However, despite these advancements, the market faces several challenges hamper its growth. One of the primary barriers is the high cost associated with advanced treatments and technologies. The financial burden on healthcare systems can also limit the widespread adoption of these advanced therapies, impeding market growth. Limited access to advanced healthcare facilities and technologies in certain regions poses a significant challenge. The availability of advanced diagnostic instruments and treatment options for PAD may be limited by disparities in healthcare infrastructure between developed and developing countries and between urban and rural areas.

There is a major element that is driving the increased need for PAD therapy in France, and that is the rising prevalence of hypertension and diabetes. According to the International Diabetes Federation, approximately 3.9 million people in the country were living with diabetes as of 2021. The French healthcare system has implemented national screening programs and public health campaigns to reduce smoking rates and promote healthy lifestyles. PAD is effectively managed by prioritizing early diagnosis and advanced treatment options, as emphasized by the Ministry of Health. Hence, the European market presents a promising outlook.

Based on Product Type, the market is segmented into Drugs (Antiplatelet Medicines, Statins, Anti Hypertensive Medication, and Others), and Devices (Peripheral Stents, Peripheral Angioplasty Balloons, Peripheral Catheters, Plaque Modification Devices, Inferior Vena Cava Filters, Hemodynamic Flow Alteration Devices, and Peripheral Accessories). Based on End User, the market is segmented into Hospitals, and Specialty Clinics. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

List of Key Companies Profiled

• Becton, Dickinson and Company
• Bayer AG
• Koninklijke Philips N.V.
• Abbott Laboratories
• Terumo Corporation
• B. Braun Melsungen AG
• Medtronic PLC
• Boston Scientific Corporation
• Cardinal Health, Inc.
• Biotronik SE & Co. KG

Europe Peripheral Artery Disease Market Report Segmentation

By Product Type

• Drugs
• Antiplatelet Medicines
• Statins
• Anti Hypertensive Medication
• Others
• Devices
• Peripheral Stents
• Peripheral Angioplasty Balloons
• Peripheral Catheters
• Plaque Modification Devices
• Inferior Vena Cava Filters
• Hemodynamic Flow Alteration Devices
• Peripheral Accessories

By End User

• Hospitals
• Specialty Clinics

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe